secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206368
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q1 revenue $136M, net loss $1.84/share; reaffirms 2026 guidance; GTX-102 Phase 3 data H2 2026
--------------------------------------------------------------------------------

- Total revenue $136M (Q1 2025: $139M); Crysvita $93M, Dojolvi $18M, Evkeeza $18M, Mepsevii $7M.
- Net loss $185M ($1.84/share) vs $151M ($1.57/share); operating expenses $305M including $30M restructuring.
- Reaffirms 2026 total revenue guidance $730M-$760M; combined R&D and SG&A expenses flat to slightly down vs 2025.
- DTX401 BLA for GSDIa granted Priority Review; PDUFA Aug 23, 2026. UX111 BLA resubmitted for MPS IIIA; PDUFA Sept 19, 2026.
- GTX-102 Angelman Phase 3 data expected H2 2026; DTX301 Phase 3 showed significant ammonia reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/0001193125-26-206368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer